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Tracheobronchial tumors include primary malignant
tumors, secondary malignant tumors, and benign tumors.
Primary malignant tumors of the trachea are rare, repre-
senting only 0.1% to 0.4% of all malignant disease.
Squamous cell carcinoma (SCC) and adenoid cystic
carcinoma are the most common histological subtypes,
making up approximately two-thirds of primary tracheal
neoplasms.1 Such tumors have typically been treated with
surgical resection and adjuvant radiation therapy (RT;
Table 1). Medically inoperable tumors are usually treated
with deﬁnitive RT, but because of the rarity of these
tumors, there are no randomized trials to determine the
optimal treatment regimen.8,14
A radiation dose ofw60 Gy has been most commonly
reported for external beam RT, with higher doses havingConﬂicts of interest: None.
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using historical techniques.15-17 In contrast to deﬁnitive
RT, the use of deﬁnitive RT with concurrent chemo-
therapy for tracheal SCC has been sparingly described in
the literature.2,3,5,18 In this report, we describe our expe-
rience with 2 patients at our institution who received
deﬁnitive RT using modern techniques with concurrent
chemotherapy for tracheobronchial SCC.Case presentation
Patient 1, a 72-year-old female, initially presented with
recurrent pneumonia, thrombocytosis, and leukocytosis.
She had a 30 pack-year smoking history, but had quit for
>25 years before the presentation. The patient underwent
bronchoscopy, which revealed an inﬁltrating, granular,
endobronchial mass extending from the carina into the left
mainstem and right upper lobe bronchus (Fig 1A). The
right mainstem bronchus was 80% occluded. There was
no evidence of primary lung tumor or inﬁltration.
Tracheal biopsies were consistent with SCC. Positronof the American Society for Radiation Oncology. This is an open access
by-nc-nd/4.0/).
Table 1 Treatment and outcomes of case reports and series describing tracheobronchial cancer
Study No. of patients
(SCC/total)
Treatment (no. of
patients)
Radiation dose Median
survival
5-y OS (%) Pattern of failure
Joshi et al
(2014)2
9 total Chemo RT 60-64 Gy NR NR NR
Xie et al
(2012)3
66 SCC/156
total
RT (33) NR 73 mo 51.0 NR
No RT (33) NA 7 mo 7.6 NR
Abbate et al
(2010)4
1 SCC RT 50.4 Gy Boost
to 61.2 Gy
1 y NA NR
Hetna1 et al
(2010)5
24 SCC/50 total Surgery þ RT (3)* 64 Gy
(deﬁnitive),
35 Gy
(palliative)
NR 66* 5-y LRRFS 18%,
5-y DFS 15%RT (39)* NR 16*
Chemo-RT (4)* NR 0*
Ly et al
(2010)6
1 SCC Endotracheal ablation
and XRT (1)
66.6 Gy > 16 mo NA NR
Ahn et al
(2009)7
11 SCC/23 total Surgery (6) NA NR 50 NR
EBRT (2) NR NR 0 NR
Surgery þ EBRT (3) NR NR 50 NR
Gaissert et al
(2004)8
135 SCC/270
total
Surgical resection 
adjuvant EBRT
(90)
54 Gy adjuvant 38 mo 39 NR
Deﬁnitive RT (45) 60 Gy 8.8 mo 7.3 NR
Thotathil
et al
(2004)9
6 SCC/15 total EBRT (3) or EBRT
þ ILRT (1)
EBRT 10-56 Gy
ILRT 15 Gy
(LDR)
38 mo* 37* Local failure: 2/9
Distant failure 4/9
No treatment (2) NA
Videtic et al
(2003)10
1 SCC Chemo RT 60 Gy >2 y NR NR
Chao et al
(1998)11
28 SCC/42 total Deﬁnitive RT 50
Gy (6)
50-64 Gy* 12.4 mo* NR NR
Deﬁnitive RT <50
Gy (22)
36 Gy
(median)*
4.5 mo*
Makarewicz
et al
(1998)12
13 SCC/23 total RT 60 Gy (primary
therapy)
17 mo NR NR
20 Gy ILRT þ
30 Gy EBRT
(palliative)
Schraube
et al
(1994)13
11 SCC RT (10) 54-60 or 46-50
Gy þ 3-4 x5 Gy
High-dose
endotracheal
afterloading
31 mo NR Local failure 5/10
Distant failure 3/10
Surgery þ RT (1) 60 Gy NR NR
Chow et al
(1993)24
7 SCC/22 total Surgery (4) NA 16 mo* NR LRR 40%*
Surgery þ EBRT (1) 50-60 Gy* 146 mo NR LRR 20%*
EBRT (7) 30-68 Gy* 26 mo* NR LRR 67%*
Fields et al
(1989)16
13 SCC/24 total RT <40-70 Gy 10 mo* 25* Locoregional
failure 14/24*
Distant failure
12/24*
Surgery þ RT
Cheung
(1989)17
20 SCC/24 total EBRT (2
orthovoltage, 17
megavoltage)
13-70 Gy 5 mo NR NR
DFS, disease-free survival; EBRT, external beam radiation therapy; ILRT, intraluminal radiation therapy; LRRFS, locoregional recurrence-free
survival; NA, not applicable; NR, not reported; RT, radiation therapy; SCC, squamous cell cancer.
* No subgroup analysis by squamous histology reported.
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Figure 1 Patient 1 (A) Pretreatment bronchoscopy photograph of distal trachea with granular mass, (B) Radiation treatment plan with
56 Gy isodose line indicated in purple; (C) posttreatment bronchoscopy of distal trachea. Patient 2 (D) pretreatment bronchoscopy
photograph with nodularity of distal trachea; (E) radiation treatment plan with 62 Gy isodose line indicated in green. (F) Patient
posttreatment bronchoscopy of distal trachea.
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further revealed a ﬂudeoxyglucose (FDG) avid right
paratracheal node and was thus consistent with stage IV
disease under the Bhattacharyya staging system.19 Given
the extensive tracheal involvement, the patient was not
considered a surgical candidate. The patient was treated
with 60 Gy external beam RT in 30 fractions using
3-dimensional conformal techniques (Fig 1C) with con-
current weekly carboplatin and Taxol. The internal target
volume included the trachea, right mainstem bronchus,
right paratracheal node, and right hilum with a clinical
target volume (CTV) margin of 3 to 5 mm axially and 7 to
10 mm superiorly and inferiorly. There was no elective
nodal irradiation. The mean lung dose delivered was
17.9 Gy with a V20 (percentage of lung receiving 20 Gy)
of 35.7% and V5 of 67.0%. The mean dose delivered to
the esophagus was 32.3 Gy with a V55 of 46%.
She experienced side effects of mild odynophagia and
dysphagia (Radiation Therapy Oncology Group [RTOG]
grade 2) treated by hydrocodone and acetaminophen. She
also experienced signiﬁcant fatigue requiring intravenous
hydration. At 3 months’ posttreatment, she developed
grade 2 radiation pneumonitis that resolved with predni-
sone. She developed distant recurrence at 12 months with
renal metastasis. PET scan showed an FDG uptake in the
left kidney with no abnormal uptake in the thorax.
Bronchoscopy showed no evidence of endobronchial
lesions (Fig 1B). The patient died of progressive disease
at 15 months. She had no evidence of local recurrence.
Patient 2, a 63-year-old female, initially presented with
a productive cough. She had a 60 pack-year history ofsmoking but had quit 5 years before presentation. Bron-
choscopy revealed multiple endotracheal and endobron-
chial nodules beginning 1 cm below the vocal cords
extending to the carina and along the left mainstem
bronchus (Fig 1D; Appendix E1; available as supple-
mentary material online only at www.practicalradonc.
org). There was no evidence of disease in the right
airway. Biopsy revealed SCC in situ with suspected focal
invasion. PET CT showed slight FDG uptake in the
trachea from the sternal notch to the carina, left mainstem
bronchus, and left hilum, consistent with Bhattacharyya
stage III. There was no evidence of primary lung tumor or
inﬁltration into bronchus. Given the extensive involve-
ment of the airway, the patient was treated with 66 Gy in
33 fractions using IMRT (Fig 1F) with 2 cycles of con-
current cisplatin and etoposide. Given the difﬁculty of
visualizing disease extent, we used PET CT, bronchos-
copy videos, and discussions with the thoracic surgeon
and pulmonologist who performed the bronchoscopy to
identify anatomic landmarks to demarcate the extent of
disease. The internal target volume included the trachea
and left mainstem bronchus with a 3 mm CTV margin
axially and a 7 mm CTV margin superiorly and inferiorly.
There was no elective nodal irradiation. The mean lung
dose was 14.2 Gy with a V20 of 27.3% and a V5 of
50.3%. The mean dose to the esophagus was 36.9 Gy
with a V55 of 51%.
During treatment, the patient developed moderate
dysphagia and esophagitis (RTOG grade 1) and subse-
quent difﬁculty with oral intake requiring multiple ad-
ministrations of intravenous ﬂuids, but able to eat a
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titis with moist desquamation of the anterior neck.
Surveillance bronchoscopies at 4 and 9 months showed
no residual or recurrent disease. However, the patient
developed hemoptysis at 11 months after chemo-RT.
Bronchoscopy at 14 months showed no evidence of
disease; however, biopsies of the left mainstem bronchus
revealed SCC in situ. Chest CT at this time also revealed
multiple bilateral pulmonary nodules suspicious for met-
astatic disease. The patient was hospitalized multiple
times with hypoxia, and a chest CT at 16 months revealed
an increase in bilateral pulmonary nodules consistent with
metastatic disease. The patient died at 17 months.Discussion
Given the rarity of tracheobronchial tumors, there have
been no randomized controlled trials to determine the
optimal therapy. The preferred form of therapy is surgical
resection with adjuvant RT because of its favorable
outcomes over RT alone. The reported 5-year survival
rate for surgically treated patients is 41% to 57%
compared with 6% to 11% for patients treated with
deﬁnitive radiation.7,8,20 Yet, up to one-third of patients
with tracheal cancer may not be surgical candidates, most
often because of the extent of locoregional disease.8 For
patients who are not surgical candidates, the choice of
treatment has generally been RT, with few studies
describing the use of chemotherapy for tracheal SCC.5,10
This report expands on the existing literature by
describing the treatment of 2 patients with deﬁnitive RT
and concurrent chemotherapy.
As a result of advances in surgical techniques, the
majority of patients with tracheobronchial disease are
candidates for surgery. Resection of up to one-half of the
length of the adult trachea is feasible with modern
mobilization techniques.21 Adjuvant radiation is generally
recommended for resectable SCC and adenoid cystic
carcinoma.3,14 Because of the narrow margins of resection
achieved in tracheal surgery, Grillo and Mathisen rec-
ommended the use of postoperative radiation in all cases,
including those with negative margins and lymph
nodes.14 Contraindications to surgery include metastatic
disease, invasion of adjacent organs, involvement of
airway greater than could be safely resected (>50% of
trachea), involvement of airway that would leave grossly
positive margins after resection, spinal kyphosis, or poor
medical condition of the patient.8,22,23
There remains a high mortality for patients with
unresectable tracheal cancer and thus prompts an exami-
nation of the reported treatments for these patients, which
has generally been limited to external beam RT,4,11-13,16
with some reports of brachytherapy9,12 and endotracheal
ablation.6 Review of the literature indicates that local
recurrence is the most common pattern of failure fortracheobronchial SCC with rates between 19% and
73%.5,8,13 However, distant failure is also substantial,
reported between 13% and 46%, supporting the potential
inclusion of chemotherapeutic regimens for the treatment
of this disease.
Although concurrent chemoradiation is used in non-
small cell carcinoma and head and neck cancer, there are
few reports describing its use in tracheobronchial tumors.
Videtic et al reported 1 patient with tracheal SCC who
received 2 cycles of induction cisplatin, etoposide, leuco-
vorin, and 5-ﬂuorouracil followed by 2 cycles of cisplatin,
etoposide, leucovorin, and 5-ﬂuorouracil concurrent with
60 Gy RT (30 fractions), resulting in survival greater than
2 years.10 Hetna1 et al demonstrated the use of etoposide
and cisplatin after RT (median, 64 Gy) in 4 patients with
tracheal cancer, but did not report a median survival rate for
these patients.5 Joshi et al expanded on these results
with a recent series of 9 patients treatedwith radiation (CTV
90, 62.5 Gy) and concurrent chemotherapy (paclitaxel
50 mg/m[2] and carboplatin area under the curve Z 2
weekly).2 Although target volumes are not clearly
described in many reports, several case series of deﬁnitive
RT have included hilar nodes, subcarinal nodes, and
mediastinal nodes within their target volumes.5,12,13
Further details regarding the radiation dose delivery (such
as CTV margin) have not been clearly described in histor-
ical reports.
The patients in this report were treated with RT and
concurrent chemotherapy. We report an overall survival
of 15 and 17 months. This appears to be comparable
or better than prior reports of SCC treated with deﬁnitive
RT. However, reported rates of overall survival with
deﬁnitive RT are difﬁcult to compare because of hetero-
geneous presentations and a lack of consistent staging
in prior reports. Chao et al report a median survival of
only 5.7 months in their cohort (42 patients, 67% SCC)
treated with RT alone. Median survival was poorer for
patients with lymph node involvement at 4.6 months.11
Gaissert et al similarly described median overall sur-
vival of 8.8 months for patients with unresectable SCC.8
Two series have reported higher rates of survival for
deﬁnitive radiation. Makarewicz et al describe a median
survival of 17 months in 13 patients treated with 60 Gy
RT.12 However, only 3 of these patients had nodal
involvement, and only 1 patient had mainstem bronchus
involvement. Similarly, Schraube et al13 report a median
survival of 31 months for 11 SCC patients treated with
deﬁnitive RT, which appears to be higher than other re-
ports.14 The authors of this study acknowledge that their
reported higher rate of survival may be attributed to lack
of mediastinal lymph node involvement in 7 of 11 pa-
tients. Chow et al also report a median overall survival of
26 months; however, this analysis was not limited to
patients with SCC.24 Thus, it is not clear whether the
patients in these studies represent earlier stage or less
aggressive disease compared with patients in our report
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involvement.
Notably, patients in this report tolerated therapy well
with the use of modern RT techniques and dose delivery
to 60 to 66 Gy to large extents of the central airways. The
most signiﬁcant adverse effect was RTOG grade
2 esophagitis and grade 2 radiation pneumonitis. Neither
of the patients required nutritional support via feeding
tube during or after therapy. Of note, the grade 2 pneu-
monitis was observed in the patient with 3-dimensional
conformal planning with lung metrics of V20 Z 35.7%
and V5 Z 67.0.%, whereas pneumonitis did not occur
with the use of IMRT for patient 2.
This report provides evidence for the use of concurrent
chemotherapy and RT using modern techniques with
no signiﬁcant severe toxicity for SCC of the trachea.
This supports the few reports that have been published
documenting the use of concurrent chemoradiation for
this tumor2,5,18 as well as other tracheobronchial tu-
mors.25 Because of the limited number of patients
treated, additional data will be required to validate the
efﬁcacy of chemoradiation in comparison to primary
RT alone for unresectable cases and subsequently identify
improved systemic therapies. Given the high rate of
distal recurrence in other reports and in our 2 patients,
further investigation into the potential role of additional
therapies, such as adjuvant chemotherapy or immuno-
therapy, may be worth exploring. Notably, these patients
did not have metastatic tracheal disease or direct exten-
sion of bronchogenic carcinoma. Thus, the applicability
of this report to such disease presentations is unclear.
However, our initial ﬁndings suggest the use of concur-
rent chemotherapy may be considered in addition
to RT in patients with locally advanced or late stage
tracheal SCC.
Supplementary data
Supplementary material for this article (http://dx.doi.
org/10.1016/j.adro.2016.03.003) can be found at www.
practicalradonc.org.
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